![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Dose of Lupin’s Budesonide Inhalation Suspension
FDA Approves Dose of Lupin’s Budesonide Inhalation Suspension
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
November 20, 2018
Lupin received another approval from the FDA for its Budesonide inhalation suspension, a generic version of AstraZeneca’s long-term maintenance treatment, Pulmicort Respules, used to control and prevent asthma symptoms in children.
The agency approved the 0.5mg/2 mL single-dose ampules of Budesonide’s inhalation suspension for use in children 12 months to eight years of age.
The generic is not an adequate treatment for a severe asthma attack and should only be used with a jet nebulizer device connected to an air compressor, the agency said.
Upcoming Events
-
21Oct